- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05963412
Online Individual Intervention Program to Make Sense of People's Experiences After a Breast Cancer Diagnosis
Developing an Online Individual Intervention Program to Make Sense of People's Experiences After a Breast Cancer Diagnosis and Examining Its Effectiveness
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In recent years, there has been a growing discussion about the necessity for mental health services not only to alleviate individuals' psychological distress but also to focus on enhancing the sense of meaning in life. Therefore, the MCCP aimed not only to reduce distressing psychological symptoms but also to facilitate the discovery of new positive meanings in breast cancer and individual's life, despite existing limitations. In this regard, the MCCP has been developed by drawing upon Meaning-Making Model, principles of meaning therapy, the literature on meaning, and existing meaning centered psychotherapy approaches. Additionally, considering limitations such as potential program changes, transportation difficulties, and inadequate physical conditions, online interventions offer a reliable alternative that provides numerous advantages for individuals diagnosed with breast cancer. Therefore, the intervention program was implemented online via video conference for women diagnosed with breast cancer in the current study. After the program was developed, a pilot study was conducted. According to the expert's feedback, the final version of MCCP was developed. The primary aim was to test the effectiveness of MCCP among women with breast cancer. The research hypotheses are 1) compared to control grup, MCCP group would show better improvement in meaning in life and PTG scores 2) compared to control grup, MCCP group would show better improvements in situational meaning (i.e. stress appraisal 3)Compared to control group, the MCCP group would report a significantly lower level of psychological distress.
Before the data collection process, ethical approval was obtained from the Institutional Ethics Committee of Dokuz Eylül University, affiliated with Dokuz Eylül University School of Medicine (Ethics Committee Decision No: 2021/12-39). The study has been announced using social media platforms (Facebook, Twitter, Instagram), oncology associations established to support oncology patients, and referrals from healthcare professionals to reach potential participants. The sample size was determined using the power analysis method. Then, 44 women diagnosed with breast cancer who volunteered to participate in the study were randomly assigned to either the intervention group or the waitlist control group.
The random assignment process was conducted using the website https://www.randomizer.org/. Participants in the MCCP group were assessed thrice: before the intervention, immediately after the intervention, and at the 2-month follow-up. The control group underwent the initial assessment before intervention began and the final assessment took place eight weeks later. After getting verbal and written consent from all participants, a number of measurement tools was applied. The Sociodemographic and Disease-Related Information Form, The Meaning in Life Questionnaire, Posttraumatic Growth Inventory-X, Stress Appraisal Measure, and Hospital Anxiety and Depression Scale were used. To test the hypotheses of the study, Pearson correlation analysis, 2 (Group) X 2 (Time) repeated measures ANOVA, and one-way repeated measures ANOVA were applied. SPSS 29.0 Package Program for Social Sciences was used for statistical analyses.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
İzmir, Turkey, 35390
- Dokuz Eylul University, Faculty of Letters
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion criteria:
- Age between 18 and 65 years
- Being a woman
- Being a native Turkish speaker
- Diagnosed with stage I, II, or III breast cancer
- Diagnosed for at least 6 months and at most 3 years
- Being able to video-conference using a desktop computer, a laptop, or a tablet
Exclusion criteria:
- Having any psychiatric diagnosis or currently using psychiatric medication,
- Currently receiving psychological support,
- Having a history of cancer diagnosis
- Having a diagnosis of advanced stage (stage ıv) breast cancer
- Having a concurrent diagnosis of another cancer.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Online Individual Intervention Program
The online intervention program (namely, Meaning-Centered Coping Program) consists of eight individual sessions, each lasting approximately 60 min.
Sessions were conducted per week.
|
Meaning Centered Coping Program is a psychological intervention program developed for women diagnosed with breast cancer, based on the Meaning Making Model (Park, 2010; Park and Folkman, 1997) and Wong's (2010) principles of Meaning Therapy. Each weekly session had specific topics. These are: Session 1: Guiding patients to tell the story of their breast cancer and psycho-education; Session 2: Encouraging patients to talk about the effects of breast cancer on their lives and learning to accept their difficult emotions; Session 3: Focusing on cognition through the meaning attributed to breast cancer; Session 4: Learning to take alternative perspectives and defusing their negative thoughts; Session 5: Exploring personal strengths; Session 6: İdentifying important life values and moving toward value-based actions; Session 7: Finding meaning in breast cancer and life; Session 8: Focusing on Future plans and hopes |
|
No Intervention: No Intervention: Waitlist Control Group
A wait-list control group was used.
Participants assigned to the wait-list control group did not receive the intervention immediately.
After the final assessment was administered (eight weeks later since the initial assessment), they were able to participate in the same intervention program if they wanted.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Socio-demographic and Disease-Related Information Form
Time Frame: Baseline (before the intervention program begins)
|
This form is a questionnaire designed to gather socio-demographic characteristics and information related to the diagnosis of breast cancer from the participants.
Socio-demographic questions include the participant's age, educational level, occupation, income level, marital status, the number of children, and health insurance coverage.
The questions related to breast cancer include the time since diagnosis, clinical stage of breast cancer, duration of treatment, completed treatment, type of surgical interventions, cancer history and menstrual status.
|
Baseline (before the intervention program begins)
|
|
Change in the Meaning in Life Questionnaire
Time Frame: Baseline (before the intervention program), post-intervention at 8 week (after the intervention program) and at the 2-month follow-up
|
The Meaning in Life Scale was developed to measure individuals' level of meaning and purpose in life (Steger et al., 2006) The scale consists of a total of ten items and comprises two dimensions: the presence of meaning and the search for meaning.
The scale is assessed using a 7 point scale scored from 1 to 7. The Turkish version of The Meaning in Life Questionnaire, adapted by Akin and Taş (2015), was used in this study.
Psychometric features of the Turkish version of the scale indicated that it was a valid and reliable measurement tool.
|
Baseline (before the intervention program), post-intervention at 8 week (after the intervention program) and at the 2-month follow-up
|
|
Change in Post-traumatic Growth Inventory-X
Time Frame: Baseline (before the intervention program), post-intervention at 8 week (after the intervention program) and at the 2-month follow-up.
|
The Posttraumatic Growth Inventory (PTGI) is developed to assess positive changes experienced following traumatic life events.
In this study, the Posttraumatic Growth Inventory-X (PTGI-X) was used (Tedeschi et al., 2017).
The inventory consists of 25 items and is scored on a six-point scale scored from 0 to 5. Higher scores on the inventory indicated higher levels of posttraumatic growth.
The Psychometric properties of the inventory are sufficient to measure the level of post-traumatic growth.
|
Baseline (before the intervention program), post-intervention at 8 week (after the intervention program) and at the 2-month follow-up.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in The Stress Appraisal Measure
Time Frame: Baseline (before the intervention program), post-intervention at 8 week (after the intervention program) and at the 2-month follow-up.
|
The scale developed by Peacock and Wong (1990) is designed to assess the cognitive evaluation of stress.
It consists of 24 items.
The items are evaluated using a likert scale scored from 1 to 5. The scale comprises five subscales that involve primary (threat and challenge) and secondary appraisals (uncontrollable-by-anyone, controllable-by-self, and controllable-by-others).
The scale is recommended by Park and George (2013) for assessing situational meaning.
The Turkish version of the scale was used for this purpose in the current study.
|
Baseline (before the intervention program), post-intervention at 8 week (after the intervention program) and at the 2-month follow-up.
|
|
Change in Global Meaning Violation Scale
Time Frame: Baseline (before the intervention program), post-intervention at 8 week (after the intervention program) and at the 2-month follow-up.
|
The scale developed by Park and colleagues (2016) is designed to assess disruptions in global meaning following a traumatic or stressful life event.
It consists of 13 items.
Each item of the scale is evaluated using a five-point scale scored from 1 to 5. Psychometric results demonstrated that the Turkish version of the scale was valid and reliable (Acet et al., 2020).
|
Baseline (before the intervention program), post-intervention at 8 week (after the intervention program) and at the 2-month follow-up.
|
|
Change in The Impact of Event Scale-Revised
Time Frame: Baseline (before the intervention program), post-intervention at 8 week (after the intervention program) and at the 2-month follow-up.
|
The scale was developed to assess traumatic stress symptoms (Weiss,2004).
It consists of 22 items, which are evaluated using a Likert scale scored from 0 to 4. The scale comprises three subscales.
These are intrusion, avoidance, and hyperarousal .
The adaptation of the scale to Turkish was conducted by Çorapçıoğlu and colleagues (2006).
Within the scope of the current study, intrusions and avoidance were used to assess automatic meaning-making efforts.
|
Baseline (before the intervention program), post-intervention at 8 week (after the intervention program) and at the 2-month follow-up.
|
|
Change in Acceptance and Action Questionnaire-II
Time Frame: Baseline (before the intervention program), post-intervention at 8 week (after the intervention program) and at the 2-month follow-up.
|
The Acceptance and Action Questionnaire-II (AAQ-II) was developed to measure psychological inflexibility/flexibility (Bond et al., 2011).
The scale consists of a total of seven items, each of which is rated on a seven-point scale scored from 1 to 7. Higher scores on the scale indicate higher levels of psychological inflexibility.
The scale has been adapted into Turkish by Meunier and colleagues (2014).Turkish version of the scale demonstrated adequate psychometric properties.
|
Baseline (before the intervention program), post-intervention at 8 week (after the intervention program) and at the 2-month follow-up.
|
|
Change in The Hospital Anxiety and Depression Scale
Time Frame: Baseline (before the intervention program), post-intervention at 8 week (after the intervention program) and at the 2-month follow-up.
|
The scale was developed by Zigmond and Snaith (1983) to assess the levels of depression and anxiety in individuals diagnosed with various physical illnesses.
The scale consists of a total of 14 items, with seven items evaluating anxiety and another seven items assessing depression levels.
Participants are asked to rate each item on a four-point scale ranging from 0 to 3. The Turkish validity and reliability study of the Hospital Anxiety and Depression Scale (HADS) was conducted by Aydemir and colleagues (1997).
The HADS is a valid and reliable measurement tool for assessing anxiety and depression levels in samples with a medical diagnosis.
|
Baseline (before the intervention program), post-intervention at 8 week (after the intervention program) and at the 2-month follow-up.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Selva Ülbe, Dokuz Eylul University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MeaningInt-BreastCancer
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Oncoliq US IncRecruitingBreast Cancer Female | Breast Cancer Detection | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Breast Cancer With Low to Intermediate HER2 Expression | Breast Cancer - Female | Breast Cancer (Early Breast Cancer) | Breast Cancer - Ductal Carcinoma in Situ (DCIS) | Breast Cancer - Infiltrating...Argentina
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
-
Joseph Baar, MD, PhDCompletedBreast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast CancerUnited States
-
Case Comprehensive Cancer CenterNational Institute on Minority Health and Health Disparities (NIMHD)CompletedCancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
Clinical Trials on Meaning Centered Coping Program
-
Duke UniversityAmerican Cancer Society, Inc.CompletedPain | Advanced Solid TumorUnited States
-
Duke UniversityIcahn School of Medicine at Mount SinaiCompleted
-
Duke UniversityCompleted
-
Fordham UniversityCalvary Hospital, Bronx, NYNot yet recruiting
-
Memorial Sloan Kettering Cancer CenterActive, not recruiting
-
Mayo ClinicNot yet recruitingHematopoietic Stem Cell TransplantUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingBreast Cancer | Colorectal Cancer | Prostate Cancer | Breast Cancer Stage IV | Thyroid Cancer | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Breast Cancer Stage III | Prostate Cancer Stage III | Prostate Cancer Stage IV | Thyroid Cancer Stage IV | Thyroid Cancer Stage IIIUnited States, Mexico
-
Memorial Sloan Kettering Cancer CenterFordham UniversityCompletedPalliative CareUnited States
-
National Center for Complementary and Integrative...Completed